19-Hydroxyandrost-4-ene-3,17-dione (BioDeep_00000005777)
Main id: BioDeep_00000016574
human metabolite Endogenous blood metabolite Volatile Flavor Compounds
代谢物信息卡片
化学式: C19H26O3 (302.1881846)
中文名称: 19-羟基雄甾-4-烯-3,17-二酮
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC12CCC3C(C1CCC2=O)CCC4=CC(=O)CCC34CO
InChI: InChI=1S/C19H26O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10,14-16,20H,2-9,11H2,1H3/t14-,15-,16-,18-,19+/m0/s1
描述信息
19-hydroxyandrost-4-ene-3,17-dione, also known as 19-haed, belongs to androgens and derivatives class of compounds. Those are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Thus, 19-hydroxyandrost-4-ene-3,17-dione is considered to be a steroid lipid molecule. 19-hydroxyandrost-4-ene-3,17-dione is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). 19-hydroxyandrost-4-ene-3,17-dione can be found in a number of food items such as red huckleberry, chinese chestnut, mustard spinach, and komatsuna, which makes 19-hydroxyandrost-4-ene-3,17-dione a potential biomarker for the consumption of these food products. 19-hydroxyandrost-4-ene-3,17-dione can be found primarily in blood, as well as in human placenta and testes tissues. In humans, 19-hydroxyandrost-4-ene-3,17-dione is involved in a couple of metabolic pathways, which include androgen and estrogen metabolism and androstenedione metabolism. 19-hydroxyandrost-4-ene-3,17-dione is also involved in a couple of metabolic disorders, which include 17-beta hydroxysteroid dehydrogenase III deficiency and aromatase deficiency. Moreover, 19-hydroxyandrost-4-ene-3,17-dione is found to be associated with cushings Syndrome.
19-Hydroxyandrost-4-ene-3,17-dione is a substrate for Corticotropin-lipotropin and Cytochrome P450 19A1.
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
同义名列表
10 个代谢物同义名
(1S,2S,10R,11S,15S)-2-(hydroxymethyl)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione; 19-Hydroxy-4-androstene-3,17-dione, 18O-labeled; 19-Hydroxy-4-androstene-3,17-dione; 19-hydroxyandrost-4-ene-3,17-dione; 19-Hydroxy-4-androsten-3,17-dione; 19-Hydroxyandrostenedione; Dienogest Impurity 1; 19-HAED; 19-Hydroxyandrost-4-ene-3,17-dione; 19-Hydroxyandrost-4-ene-3,17-dione
数据库引用编号
18 个数据库交叉引用编号
- ChEBI: CHEBI:27576
- KEGG: C05290
- PubChem: 521310
- PubChem: 252379
- HMDB: HMDB0003955
- Metlin: METLIN6990
- ChEMBL: CHEMBL4517318
- foodb: FDB030282
- chemspider: 221136
- CAS: 61342-08-3
- CAS: 510-64-5
- PMhub: MS000018646
- PubChem: 7675
- LipidMAPS: LMST02020067
- 3DMET: B01834
- NIKKAJI: J117.011B
- RefMet: 19-Hydroxyandrost-4-ene-3,17-dione
- KNApSAcK: 27576
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
20 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(2)
- estradiol biosynthesis I:
17β-estradiol + NAD(P)+ ⟶ H+ + NAD(P)H + estrone
- estradiol biosynthesis I (via estrone):
O2 + a reduced [NADPH-hemoprotein reductase] + androst-4-ene-3,17-dione ⟶ 19-hydroxyandrostenedione + H2O + an oxidized [NADPH-hemoprotein reductase]
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(18)
- Androgen and Estrogen Metabolism:
Estradiol + NADP ⟶ Estrone + NADPH
- 17-beta Hydroxysteroid Dehydrogenase III Deficiency:
Estradiol + NADP ⟶ Estrone + NADPH
- Aromatase Deficiency:
Estradiol + NADP ⟶ Estrone + NADPH
- Androstenedione Metabolism:
Androstanedione + Hydrogen Ion + NADH ⟶ Androsterone + NAD
- Androgen and Estrogen Metabolism:
Estradiol + NADP ⟶ Estrone + NADPH
- Androstenedione Metabolism:
Androstanedione + Hydrogen Ion + NADH ⟶ Androsterone + NAD
- 17-beta Hydroxysteroid Dehydrogenase III Deficiency:
Estradiol + NADP ⟶ Estrone + NADPH
- Aromatase Deficiency:
Estradiol + NADP ⟶ Estrone + NADPH
- Androgen and Estrogen Metabolism:
Estradiol + NADP ⟶ Estrone + NADPH
- Androstenedione Metabolism:
Androstanedione + Hydrogen Ion + NADH ⟶ Androsterone + NAD
- Androgen and Estrogen Metabolism:
Estradiol + NADP ⟶ Estrone + NADPH
- Androstenedione Metabolism:
Androstanedione + Hydrogen Ion + NADH ⟶ Androsterone + NAD
- Androgen and Estrogen Metabolism:
Estradiol + NADP ⟶ Estrone + NADPH
- Androstenedione Metabolism:
Androstanedione + Hydrogen Ion + NADH ⟶ Androsterone + NAD
- Androgen and Estrogen Metabolism:
Estradiol + NADP ⟶ Estrone + NADPH
- Androstenedione Metabolism:
Androstanedione + Hydrogen Ion + NADH ⟶ Androsterone + NAD
- 17-beta Hydroxysteroid Dehydrogenase III Deficiency:
Estradiol + NADP ⟶ Estrone + NADPH
- Aromatase Deficiency:
Estradiol + NADP ⟶ Estrone + NADPH
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- C K Sites, E H Taylor, S J Lewis, J R Brumsted. Development of a sensitive porcine granulosa cell bioassay for follicle-stimulating hormone (FSH).
Journal of assisted reproduction and genetics.
1996 Jul; 13(6):505-10. doi:
10.1007/bf02066533
. [PMID: 8835681] - H Sekihara, K Yonemitsu, Y Yazaki. Plasma 19-hydroxyandrostenedione is elevated in patients with high renin essential hypertension.
Clinical endocrinology.
1993 Nov; 39(5):557-60. doi:
10.1111/j.1365-2265.1993.tb02409.x
. [PMID: 8252745] - J I Raeside, R L Renaud, R M Friendship, M W Khalil. Secretion of 19-hydroxyandrostenedione and 19-hydroxytestosterone by porcine Leydig cells in vitro and in vivo.
The Journal of endocrinology.
1993 May; 137(2):281-9. doi:
10.1677/joe.0.1370281
. [PMID: 8326254] - T Mune, H Morita, K Yasuda, M Murayama, N Yamakita, K Miura. Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone.
Clinical endocrinology.
1993 Mar; 38(3):265-72. doi:
10.1111/j.1365-2265.1993.tb01005.x
. [PMID: 8384536] - H Morita, T Mune, K Yasuda, N Yamakita, S Miyazaki, K Miura. Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma.
Endocrine journal.
1993 Feb; 40(1):89-97. doi:
10.1507/endocrj.40.89
. [PMID: 7951501] - H Morita, T Mune, K Yasuda, L B Mercado-Asis, M Murayama, N Yamakita, S Miyazaki, K Miura. Secretory regulation of 19-hydroxyandrostenedione in normal man.
Endocrinologia japonica.
1992 Oct; 39(5):431-8. doi:
10.1507/endocrj1954.39.431
. [PMID: 1478184] - C Tosti-Croce, R Rinaldi, M Massaria, A Lomurno, T Felicioli, F Sciarra. Plasma 19-hydroxy-androstenedione (19-OH-A) in essential hypertension.
Clinical and experimental hypertension. Part A, Theory and practice.
1992; 14(6):1083-94. doi:
10.3109/10641969209038194
. [PMID: 1330385] - H Murase, K Yasuda, L B Mercado-Asis, A Mori, T Shimada, T Mune, H Morita, N Noritake, N Yamakita, K Miura. 19-hydroxyandrostenedione does not modulate [3H]aldosterone binding to human mononuclear leucocytes and rat renal cytosol.
The Journal of steroid biochemistry and molecular biology.
1991 Mar; 38(3):331-7. doi:
10.1016/0960-0760(91)90104-d
. [PMID: 2009224] - Y Osawa, S Ohnishi, C Yarborough, S Ohigashi, T Kosaki, M Hashino, T Yanaihara, T Nakayama. Serum level of 19-hydroxyandrostenedione during pregnancy and at delivery determined by gas chromatography/mass spectrometry.
Steroids.
1990 Apr; 55(4):165-9. doi:
10.1016/0039-128x(90)90105-k
. [PMID: 2339447] - M Minato, M Honda, M Hatano. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
Nihon Naibunpi Gakkai zasshi.
1990 Jan; 66(1):29-41. doi:
10.1507/endocrine1927.66.1_29
. [PMID: 2307256] - K Higuchi, A Ogo, T Maki, M Haji, R Takayanagi, M Ohashi, H Nawata, K Kato, H Ibayashi. Evidence for age-related change in plasma 19-hydroxyandrostenedione.
Endocrinologia japonica.
1989 Dec; 36(6):881-5. doi:
10.1507/endocrj1954.36.881
. [PMID: 2561277] - S Ohigashi, T Kosaki, M Hashino, T Yanaihara, T Nakayama, S Onishi, Y Osawa. [The newly developed method of 19-OH-A as intermediate of estrone biosynthesis by GC-MS].
Nihon Naibunpi Gakkai zasshi.
1989 Aug; 65(8):750-61. doi:
10.1507/endocrine1927.65.8_750
. [PMID: 2806683] - M E Hähnel, J D Martin, R Hähnel. Plasma 19-hydroxyandrostenedione and androstenedione levels in hydatidiform moles and early pregnancies with and without hypertensive diseases.
The Australian & New Zealand journal of obstetrics & gynaecology.
1989 Aug; 29(3 Pt 1):238-41. doi:
10.1111/j.1479-828x.1989.tb01727.x
. [PMID: 2604654] - Y Shimizu, T Kosaki, M Hashino, K Sugisaki, T Yanaihara, T Nakayama, Y Osawa. [Non-aromatizing androgen 19-hydroxylase in human fetal organs].
Nihon Naibunpi Gakkai zasshi.
1989 Jul; 65(7):653-62. doi:
10.1507/endocrine1927.65.7_653
. [PMID: 2583312] - M W Khalil, P Morley, M A Glasier, D T Armstrong, T Lang. Formation of 4-oestrene-3,17-dione (19-norandrostenedione) by porcine granulosa cells in vitro is inhibited by the aromatase inhibitor 4-hydroxyandrostenedione and the cytochrome P-450 inhibitors aminoglutethimide phosphate and ketoconazole.
The Journal of endocrinology.
1989 Feb; 120(2):251-60. doi:
10.1677/joe.0.1200251
. [PMID: 2926299] - M Honda, M Minato, R Takayama, Y Nagashima, M Watanabe, Y Izumi, N Fukuda, M Soma, T Shiratsuchi, Y Watanabe. [Studies on the pressor mechanism of 19-hydroxyandrostenedione].
Nihon Naibunpi Gakkai zasshi.
1989 Jan; 65(1):18-31. doi:
10.1507/endocrine1927.65.1_18
. [PMID: 2524410] - H Sekihara, K Yonemitsu, F Takaku. Enhancement of the hypertensinogenic action of 19-hydroxyandrostenedione by aromatase inhibitor, delta 1-testololactone.
Endocrinology.
1987 Dec; 121(6):1931-6. doi:
10.1210/endo-121-6-1931
. [PMID: 3678133] - V Padmanabhan, S C Chappel, I Z Beitins. An improved in vitro bioassay for follicle-stimulating hormone (FSH): suitable for measurement of FSH in unextracted human serum.
Endocrinology.
1987 Sep; 121(3):1089-98. doi:
10.1210/endo-121-3-1089
. [PMID: 3113917] - E P Gomez-Sanchez, C E Gomez-Sanchez. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione.
Endocrinology.
1986 Jun; 118(6):2582-7. doi:
10.1210/endo-118-6-2582
. [PMID: 3698922] - H Sekihara, R Torii, Y Osawa, F Takaku. Angiotensin II induces the release of 19-hydroxyandrostenedione in man.
The Journal of clinical endocrinology and metabolism.
1985 Aug; 61(2):291-6. doi:
10.1210/jcem-61-2-291
. [PMID: 2989318] - R Manabe, M Honda, M Hatano. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
Nihon Naibunpi Gakkai zasshi.
1984 Nov; 60(11):1328-37. doi:
10.1507/endocrine1927.60.11_1328
. [PMID: 6526083] - H Sekihara. 19-hydroxyandrostenedione and 6 beta-hydroxyandrostenedione: new steroids regulated by the renin-angiotensin system in man.
Journal of steroid biochemistry.
1984 Jan; 20(1):383-5. doi:
10.1016/0022-4731(84)90238-3
. [PMID: 6708521] - H Sekihara. 19-Hydroxyandrostenedione: evidence for a new class of sodium-retaining and hypertensinogenic steroids.
Endocrinology.
1983 Sep; 113(3):1141-8. doi:
10.1210/endo-113-3-1141
. [PMID: 6347666] - H Sekihara. 19-Hydroxyandrostenedione: a potent hypertensinogenic steroid in man.
Journal of steroid biochemistry.
1983 Jul; 19(1A):353-8. doi:
. [PMID: 6310235]
- H Sekihara. 6 beta-Hydroxyandrostenedione: evidence for a new hypertensinogenic agent.
Clinical and experimental hypertension. Part A, Theory and practice.
1983; 5(1):1-9. doi:
10.3109/10641968309048805
. [PMID: 6339119] - H Sekihara. 19-hydroxyandrostenedione as a new hypertensinogenic agent.
Journal of steroid biochemistry.
1982 Feb; 16(2):329-31. doi:
10.1016/0022-4731(82)90185-6
. [PMID: 7043093] - W G Kelly, O De Leon, T H Rizkallah. The role of 19-hydroxy-delta4-androstene-3,17-dione in the conversion of circulating delta4-androstene-3, 17-dione to estrone.
The Journal of clinical endocrinology and metabolism.
1976 Jul; 43(1):190-4. doi:
10.1210/jcem-43-1-190
. [PMID: 947937]